Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
CEUS for Assessing TACE Treatment Response in Liver Tumors
NCT06261814Phase 2Recruiting
- Start
- Aug 2024
- Primary completion
- Jul 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sulfur hexafluoride in liver neoplasms. Primary endpoints: Recurrence at 6 months, Sensitivity at 6 months and 4 more. Started Aug 2024; status: recruiting.
02
Drugs
sulfur hexafluoride
03
Conditions
liver neoplasms
Beyond the preview
Go deeper on NCT06261814.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06261814.